Abstract
Abstract:Determining the origin of poorly differentiated adenocarcinomas remains a challenge for the pathologist. This manuscript reports the use of a panel of specific immunohistochemical stains to determine the primary site of a tumor in the colon. A 45-year-old man had a right hemicolectomy for adenocarcinoma. Immunohistochemical staining documented that the lesion was a metastasis from a primary pancreatic adenocarcinoma—an unusual pattern of spread. The case emphasizes the important use of immunohistochemistry in identifying the primary source of lesions, allowing for appropriate treatment and staging.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
Reference1. Raghavan D, Brecher ML, Johnson DH, et al. Testbook of Uncommon Cancera. John Wiley & Sons, 2006, ed 3.2. Loos M, Kleeff J, Friess H, et al. Surgical treatment of pancreatic cancer. Ann N Y Acad Sci 2008;1138:169–180.LoosM]]KleeffJ]]FriessH&etal;Surgical treatment of pancreatic cancer.Ann N Y Acad Sci20081138169-1803. Ioachim HL. Immunobiology of metastases. Cancer Detect Prev 1991;15:127–131.IoachimHLImmunobiology of metastases.Cancer Detect Prev199115127-1314. Amezcua CA, MacDonald HR, Lum CA, et al. Endometrial cancer patients have a significant risk of harboring isolated tumor cells in histologically negative lymph nodes. Int J Gynecol Cancer 2006;16:1336–1341.AmezcuaCA]]MacDonaldHR]]LumCA&etal;Endometrial cancer patients have a significant risk of harboring isolated tumor cells in histologically negative lymph nodes.Int J Gynecol Cancer2006161336-13415. De Lott LB, Morrison C, Suster S, et al. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch Pathol Lab Med 2005;129:1100–1105.De LottLB]]MorrisonC]]SusterS&etal;CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.Arch Pathol Lab Med20051291100-11056. Groisman GM, Bernheim J, Halpern M, et al. Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum. Arch Pathol Lab Med 2005;129:920–923.GroismanGM]]BernheimJ]]HalpernM&etal;Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum.Arch Pathol Lab Med2005129920-9237. Ikeda S, Fujimori M, Shibata S, et al. Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer 2006;6:31.IkedaS]]FujimoriM]]ShibataS&etal;Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer.BMC Cancer20066318. Thaunat O, Morelon E. [Cancer and immunosuppression: pro- and antitumoral effects of immunosuppressive drug.] Nephrol Ther 2005;1:23–30 [in French].9. Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 2005;54:243–250.PavlidisN]]FizaziKCancer of unknown primary (CUP).Crit Rev Oncol Hematol200554243-250
